A randomized double-blind study to determine the effect of GK activator (2) [RO 4389620] on efficacy (HbA1c), safety, tolerability and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin.
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2016
At a glance
- Drugs Piragliatin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 21 Sep 2007 Status changed from in progress to completed.
- 20 Oct 2006 Status change